Citations

Clear

1792 citation(s) found for "Stephanie".

Palliative Ventral Hernia Repair Using Onlay Mesh and Antibiotic Beads in High-Risk Patients
Khan, Fazal Wahab , Heller, Stephanie F. , Loomis, Erica, Rivera, Mariela, Schiller, Henry J., Khan, Fazal , Heller, Stephanie, Loomis, Erica A, Schiller, Henry

Mayo Clinic

Medicina | December 31, 2025 | Volume: 62 | Issue: 1 | Pages: 74

10.3390/medicina62010074 | PMID 41597360 Get It

Background and Objectives: There are many well-described approaches to symptomatic ventral hernia management; however, there remains a significant patient population with limited options for a durable ventral hernia repair with a reasonable risk of infection and recurrence. Drawing from the orthopedic literature, we changed our approach to this clinical problem and developed a palliative ventral hernioplasty pathway. Materials and Methods: A retrospective review (2017–2019) of patients’ palliative ventral hernioplasty was performed. Results: In total, 43 patients included, with a female preponderance of 24 (58.6%) and a mean age 61.5 ± 11.5 years. The mean BMI was 38.1 kg/m2 (IQR: 25.4–62), and 28 patients (65.1%) had a history of prior wound/mesh infection. Urgent repair was performed in 14 patients. Overall polypropylene prosthetic was implanted in 26 patients, and bioprosthetic/absorbable mesh was used in the remaining. The mean surface area of the implanted mesh was 561 cm2. The most common wound complications identified were skin separation (30.2%) and seroma formation (48.8%). Hernia recurrence occurred in four (9.3%) patients, with a mean follow-up of 24.1 months (9–37). Three patients had central lightweight mesh rupture and one had a recurrence (bioprosthetic mesh); all were subsequently repaired. Conclusions: Despite the small number of patients, our palliative ventral hernia repair pathway offers durable repair with an acceptable risk of recurrence and mesh infection in patients who would otherwise be considered nonoperative.
Ebola virus matrix protein VP40 triggers inflammatory responses linked to the ebolavirus virulence
Yamaoka, Satoko , Mhamdi, Zeineb, Wang, Lin , Swenson, Vaille A. , McNally, Kristin L., Lu, Shao‐Chia , Singh, Reema , Saundh, Stephanie L. , Zell, Brady N. , Best, Sonja M. , Barry, Michael A , Ebihara, Hideki , Yamaoka, Satoko , Zell, Brady , Wang, Lin , Barry, Michael A. , Rasmussen, Angela L , Ebihara, Hideki

Mayo Clinic

Proceedings of the National Academy of Sciences | December 29, 2025 | Volume: 123 | Issue: 1 | Pages: No page available

10.1073/pnas.2508194123 | PMID 41461033 Get It

Uncontrolled systemic inflammatory responses are a critical pathological feature of fatal Ebola virus (EBOV) infection. While some inflammatory responses may originate from mononuclear phagocytes (MNPs), nonimmune cells vastly outnumber MNPs and may be an important source of inflammation. Here, we demonstrated that highly virulent EBOV induced a high and sustained pro-inflammatory response compared to less virulent ebolaviruses in non-MNPs through TLR4-independent NF-κB activation. We identified the EBOV matrix protein VP40 as a potent activator of NF-κB in non-MNPs, whose intrinsic inflammatory activation ability is higher than VP40 proteins from less virulent ebolaviruses. This suggests that VP40 is a virulence determinant inducing distinct degrees of pro-inflammatory responses among ebolaviruses. Mechanistically, VP40 activated the NF-κB signaling pathway, primarily via TNFR1 using a ligand-independent mechanism. These findings reveal mechanisms that may drive systemic inflammation and promote EBOV pathogenesis, suggesting potential therapeutic strategies to mitigate immune dysregulation in severe EBOV infections.
Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease
Christian, Bradley T, Schultz, Stephanie A. , Barthélemy, Nicolas R., Ryan, Natalie S. , Renton, Alan E., Vermunt, Lisa, Joseph‐Mathurin, Nelly, Shirzadi, Zahra , Strain, Jeremy F. , Chrem, Patricio, Daniels, Alisha , Chhatwal, Jasmeer P. , Cruchaga, Carlos, Ibanez, Laura, Jucker, Mathias, Day, Gregory S, Lee, J.R, Supnet‐Bell, Charlene, Xiong, Chengjie, Schindler, Suzanne E., Wang, Guoqiao, Li, Yan, Koeppe, Robert A., Jack, Clifford R., Morris, John C., Bateman, Randall J., Benzinger, Tammie L.S., Gordon, Brian A., (DIAN), The Dominantly Inherited Alzheimer Network, Wisch, Julie K. , McKay, Nicole S. , Zammit, Matthew D. , Christian, Bradley T. , Millar, Peter R , Barthélemy, Nicolas R. , Renton, Alan , Vermunt, Lisa , Joseph‐Mathurin, Nelly , Cruchaga, Carlos , Ibanez, Laura , Jucker, Mathias , Day, Gregory S. , Xiong, Chengjie , Llibre‐Guerra, Jorge J. , Aguillon, David , Roh, Jee Hoon , Xiong, Chengjie , Schindler, Suzanne E. , Wang, Guoqiao , Li, Yan , Koeppe, Robert A., Jack, Clifford R. , Morris, John C. , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Betthauser, Tobey J. , Gordon, Brian A.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103008 Get It

Abstract Background Alzheimer Disease (AD) pathology evolves over decades, and understanding this progression is critical to the understanding of the disease and timing therapeutic interventions. Since individuals with Autosomal Dominant AD (ADAD) develop symptoms around the same age as their parent, it is possible to predict symptom onset and stage individuals by their estimated years to symptom onset (EYO). This approach does not generalize to other forms of AD, thus there is a pressing need for the timecourse of ADAD to be defined in broadly relevant terms. The objective of this project is to validate the Sampled Iterative Local Approximation (SILA) algorithm in a cohort with a known disease timecourse. SILA generates an estimate of time from amyloid positivity (A time ) based on longitudinal PET data. Method We evaluated A time in a longitudinal ADAD sample ( N = 316) with PET PiB data in three ways. First, we compared predicted age at amyloid positive (A+) to observed age at A+ for individuals who became A+ during enrollment. Next, using linear regression, we compared estimated age at A+ to estimated age at symptom onset (EYO=0). Finally, we used generalized additive models to compare the amount of variance in concurrent cognitive performance explained both A time and EYO. Result We observed a mean average error of 1.15 years between actual age at A+ ( N = 26) and the SILA‐predicted A time . Across all participants, SILA‐estimated age at A+ explained 39% of the variance in estimated age at symptom onset ( β = 0.918, p < 0.0001). Finally, we observed a nonlinear association between cognition and both A time and EYO. A time explained 19% of the variance in the general cognitive composite while EYO explained 43% of the variance. Conclusion SILA produces a valid estimate of time‐from‐amyloid positivity in ADAD. This work allows for disease stage in ADAD to be compared to staging for broad forms of AD, which was not previously possible using EYO. However, this work also illustrates that there is a high degree of heterogeneity in preclinical disease duration that is not explained by amyloid alone.
Loss of MITF activity leads to emergent cell states from the melanocyte stem cell lineage
MacMaster, Stephanie, Wyatt, Cameron , Ramsey, Emma, Vu, Hong Nhung , Steingrímsson, Eiríkur, Kenny, Colin , Patton, E. Elizabeth , Steingrimsson, Eirikur , Patton, E Elizabeth , Brombin, Alessandro , Trávníčková, Jana , Brunsdon, Hannah , Chandra, Tamir

Mayo Clinic

No container title available | December 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.23.695681 | PMID 41993564 Get It

Abstract How embryonic cells generate large clones of cells in the adult represents a fundamental question in biology. Here using melanocyte stem cells (McSCs) in the zebrafish as a model we explore the function of the master melanocyte transcription factor (MITF) in safeguarding McSCs in embryonic development and their potential to pigment large clones in the adult. MITF is well known is for its role in the specification of melanoblasts from the neural crest (NC) and their differentiation into melanocytes, yet little is known about how this activity shapes the stem cell lineages. Here, we use live imaging coupled with single-cell transcriptomics and lineage tracing to show that MITF ( mitfa in zebrafish) protects the melanocyte stem cell (McSC) fate in zebrafish. Utilizing a temperature sensitive mitfa vc7 mutant, we show that loss of Mitfa activity leads to a surprising premature and aberrant expansion of McSC progeny at the niche during embryogenesis, coupled with novel emergent transcriptional cell states. Linage tracing of McSCs from the embryonic to juvenile stages reveals Mitfa activity is subsequently required in regeneration by Schwann cell-like and melanocyte stem cell progenitors that serve as a reservoir for fast-responding pigment progenitors. Thus, the impact of Mitfa loss on the melanocyte lineage is cell-state and stage-specific. The emergent cell states resulting from mitfa loss may have important implications for understanding how reduced MITF activity contributes to human genetic disease and melanoma.
Cell type‐specific gene expression changes are associated with cerebral amyloid angiopathy and blood‐brain barrier integrity in Alzheimer's disease
Tsai, Wei, İş, Özkan , Oatman, Stephanie R., PATEL, T, Wang, Xue, Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Tutor‐New, Frederick Q, Udine, Evan, Lin, Shu S., Carnwath, Troy , Deniz, Kaancan , Nguyen, Thuy T., Liu, C, Yamazaki, Yu , Martens, Yuka A. , Zhao, Na, Carrasquillo, Minerva M., Murray, Melissa E., Bu, GuoJun, Kanekiyo, Takahisa , Ertekin‐Taner, Nilüfer, Wang, Xue, Tutor‐New, Frederick Q, Udine, Evan , Nguyen, Thuy T. , Heckman, Michael G. , Carrasquillo, Minerva M. , Murray, Melissa E. , Bu, Guojun , Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_106658 Get It

Abstract Background More than 85% of Alzheimer's disease (AD) donor brains exhibit some degree of cerebral amyloid angiopathy (CAA), which is characterized predominantly by Aβ40 deposits in the brain vasculature and can cause blood brain barrier (BBB) leakage. CAA is associated with risk of infarcts, cerebral hemorrhages, and cognitive decline. Brain cell type‐specific mechanisms that influence CAA pathology, as well as related measures such as Aβ40 biochemical measures and tight junction proteins, an indicator of BBB integrity, are still elusive. Method We performed single‐nucleus RNA sequencing (snRNAseq) of temporal cortex tissue from 79 AD donors, with varying levels of CAA co‐pathology. Measurements of soluble, insoluble and membrane‐associated fractions of brain Aβ40 and tight junction protein (claudin‐5, occludin) levels were available for these donors. We correlated these measures with cell proportions. We also conducted differential gene expression and analyses for intercellular communications and regulatory networks. Result We identified 25 clusters and annotated them with major brain cell types. There were 3 oligodendrocyte, 7 excitatory and 7 inhibitory neuronal, 2 microglial, 2 astrocytic, and 1 each for endothelial, pericytic, fibroblast, and oligodendrocyte precursor cell clusters. We found that higher CAA and Aβ40 levels correlate with reduced neuronal and increased microglial, astrocytic and vascular cell proportions. Increased tight junction proteins correlate with increased inhibitory neuronal and reduced microglial, astrocytic and vascular cell proportions. Among all clusters, one microglial, both astrocytic and the pericytic clusters have greater number of genes significantly associated with CAA, Aβ40 and tight junction protein levels. Most significant genes have negative associations with CAA and membrane‐bound Aβ40 and positive with tight junction protein measures. Using these genes as input for intercellular communications analysis, we prioritized ligand‐target interactions from microglia or astrocytes to pericytes. Some of the prioritized targets are transcription factors in pericytes. Using regulon analysis, we identified genes downstream of these transcription factors that are also significantly associated with lower CAA and membrane‐bound Aβ40 and higher tight junction protein levels. Conclusion We revealed glia‐to‐pericytes intercellular interactions and pericytic gene regulatory networks that are potentially perturbed by CAA and BBB breakdown. Future directions include analyzing external snRNAseq datasets and performing functional validations.
Wolframin‐1–expressing neurons in the entorhinal cortex propagate tau to neocortical brain regions under the amyloid pathology influence
Ikezu, Seiko , Tatsumoto, Ayaka, Gibbs, Brendan J. , Radhakishun, Stephanie, Ellison, J. W, Longtree‐Preciado, Alejandro, Ray, Nibedita Basu, Ravula, Arun Reddy , Hagita-Tatsumoto, Ayaka, Gibbs, Brendan J. , Ikezu, Tsuneya

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_106794 Get It

Abstract Background We have recently reported that wolframin‐1‐expressing (Wfs1 + ) pyramidal neurons in the entorhinal cortex layer II (ECII) that projects to the CA1 propagate phosphorylated tau (pTau) via the temporoammonic pathway, mimicking early stages of tau pathology in AD (ECII‐CA1 tau mice). We examined if amyloid pathology and human tau expression with this mouse model may change the character and distribution of tau transfer. Furthermore, using a chemogenetic approach, we aimed to determine the effect of neuronal excitability on tau transfer to the hippocampal regions in mouse brains. Method Cre‐inducible AAV expression P301L tau mutant (AAV‐Flex‐P301Ltau) was injected into the EC II region of APP NL‐G‐F human MAPT double knockin (APP NL‐G‐F : TAUKI) mice crossed with Wfs1‐Cre and Wfs1‐Cre mice at 7 months of age. Tau propagation was evaluated in the hippocampal and cortex regions by immunofluorescence using HT7 (human tau) and AT8 (pS 202 /pT 205 tau) mAbs at one‐ and 3‐months post‐injection. AAV‐Flex‐P301Ltau was co‐injected with Cre‐inducible AAV expressing hM3D(Gq) or hM4D(Gi) DREADD in the ECII in Wfs1‐Cre mice at 4 months of age, followed by subcutaneous infusion of clozapine N ‐oxide or saline via osmotic pumps for 28 days. Immunofluorescence against HT7 mAb was performed at one‐month post‐injection. Result We observed robust HT7 positivity in the CA1 and subiculum in Wfs1‐Cre mice after AAV‐Flex‐P301Ltau injection, although there was little AT8 staining at both one‐ and 3‐month. Interestingly, APP NL‐G‐F :TauKI:Wfs1‐Cre mice showed strong HT7 and AT8 positivity in the subiculum, but not in CA1 at 1‐month. Notably, p ‐tau further advanced into the visual cortex (VC) region at 3‐month in APP NL‐G‐F :TauKI:Wfs1‐Cre mice, while neither HT7 nor AT8 was positive in the VC in Wfs1‐Cre mice. Increased or suppressed neuronal excitability in the medial ECII pyramidal neurons by DREADD approach significantly induced or reduced tau propagation to the CA1 compared to the control group at one‐month post‐injection, respectively. Conclusion Our study demonstrates that APP NL‐G‐F :TAUKI:Wfs1‐Cre mice injected with P301L tau in the ECII recapitulates advanced‐stage AD pathology with amyloid beta navigating tau to the neocortical region and enhancing the maturity of tau pathology. Furthermore, ECII neuronal excitability regulates tau transfer efficiency from the ECII to CA1 region.
P2RX7 deficiency prevents tau‐mediated neurodegeneration via regulation of microglial response and suppression of extracellular vesicles containing tau and toxic mitochondrial content
Santos, Victor Bodart, Abdullah, Mohammad, Ellison, J. W, Radhakishun, Stephanie, You, Yang, Liang, Zhewei, Ikezu, Seiko , Bodart‐Santos, Victor , Ravula, Arun Reddy , You, Yang, Ikezu, Tsuneya

Mayo Clinic

Alzheimer's & Dementia | December 24, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_103649 Get It

Abstract Background We previously identified a novel mechanism describing how pathological tau transfers via extracellular vesicles (EVs) in Alzheimer's disease (AD). Targeting EV secretion to mitigate tau transfer is, therefore, a promising therapeutic approach for AD. P2X purinoreceptor 7 (P2RX7), an ATP‐gated cationic channel predominantly expressed in microglia, regulates the secretion and biogenesis of EVs. Here we investigated the effect of P2rx7 deficiency in PS19 tauopathy mouse model and by proteomic profiling of brain EVs. Method PS19: P2rx7 –/– mice at 9‐10 months of age were tested for fear conditioning and their brain sections were assessed for brain atrophy. Tau pathology was evaluated using ELISA and immunofluorescence against phosphorylated (AT8) and misfolded (Alz50) tau. Brain tissues were further assessed by bulk and single cell RNA‐seq (scRNA‐seq) and brain‐EVs were subjected to proteomic profiling by mass‐spectrometry. P2rx7 –/– mice were intracranially injected with viral vectors expressing P301L tau in neurons and mEmerald‐CD9 in microglia to visualize the secretion of microglial EVs in vivo . Mice conditional knockout (cKO) for P2rx7 in microglia, neurons and astrocytes were injected with a viral vector expressing P301L tau in entorhinal cortex for tau propagation assessment. Result PS19: P2rx7 –/– mice showed significant improvement in contextual and cued memory compared to age‐matched PS19 mice, which was accompanied by preserved cortical and hippocampal volume, and significant reduction of hippocampal synapse loss and tau pathology. By weighted gene co‐expression network analysis (WGCNA) we identified a microglial and EV‐related module strongly correlated with tau pathology which was remarkably downregulated in PS19: P2rx7 –/– mice hippocampus. PS19 mice showed increased secretion of EVs containing tau and mitochondrial proteins in the mouse brain parenchyma, which was significantly downregulated in PS19: P2rx7 –/– mice. scRNA‐seq analysis showed that P2rx7 is required for microglia conversion to inflammatory phenotype with increased expression of EV genes in PS19 mice. P2rx7 deficiency reduced microglial mEmerald‐CD9 + ‐EV secretion in mice expressing P301L tau. Moreover, microglia and neuron‐specific deletion of P2rx7 inhibit tau propagation from the entorhinal cortex to the mouse hippocampus. Conclusion Our study demonstrated a microglial P2RX7‐EV axis with potential implications on neuroinflammation and neurodegeneration associated with tau pathology, further indicating the therapeutic potential of targeting P2rx7 to ameliorate AD progression.
Investigating the role of the exposome on neuropathology and biochemical phenotypes in Alzheimer’s disease
Garofalo, Gabriela , Reddy, Joseph S. , HECKMAN, M, Oatman, Stephanie R., Wang, Xue, Nguyen, Thuy T. , Murray, Melissa E., Kanekiyo, Takahisa , Carrasquillo, Minerva M., Allen, Mariet , Ertekin‐Taner, Nilüfer, Heckman, Michael G. , Murray, Melissa E. , Dickson, Dennis W. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S7 | Pages: No page available

10.1002/alz70861_108874 Get It

Abstract Background Individual environmental exposures, the exposome, can play an influential role in the development and progression of neurodegenerative diseases such as AD. The protein components of the main AD neuropathologies, amyloid (Aβ) plaques and tau neurofibrillary tangles (NFTs), can be measured using immunohistochemical and biochemical approaches. The main genetic risk factor for AD is the APOE e4 allele. APOE levels can also be measured in the brain. We hypothesize that social determinants of health, specifically alcohol and tobacco consumption, and the area deprivation index (ADI), could play a considerable role in severity of neuropathology and brain biochemical phenotypes of AD. Method We evaluated 478 neuropathologically characterized AD donors, from the Mayo Clinic Brain Bank. 469 samples had available biochemical measures (APOE, Aβ40, Aβ42, tau, and phospho‐tau (Thr231)), collected across three isolated fractions (soluble (TBS), membrane‐bound (TX), and insoluble (FA)) of the superior temporal gyrus. Exposome variables were extracted from the available records. ADI from the Neighborhood Atlas® version from the year 2015 was obtained from de‐identified addresses. ADI, smoking and alcohol were available for 263 of these donors and were examined for association with biochemical measures using linear regression adjusting for age at death and sex. Result Higher ADI levels representing neighborhoods with increased deprivation, were nominally associated (β=0.006, p =0.01) with soluble levels of APOE. Alcohol consumption was associated with lower levels of membrane bound APOE (β=‐0.23, p =0.04). Analysis with neuropathological variables including CAA ( N =454), Braak ( N =454), Thal ( N =454), Hippocampal sclerosis ( N =453), Lewy bodies ( N =455) will also be performed. Conclusion Different components of the social exposome may impact levels of core AD proteins. Additional analyses in expanded cohorts to further explore the associations with neuropathology are ongoing. We expect that understanding how the social exposome impacts specific aspects of neurodegenerative diseases will provide key insights into underlying, potentially modifiable, mechanisms of disease.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N. , Carrillo, Maria, Casaletto, Kaitlin B, Chang, C. -C., Chang, Hsin‐I., Chao, Yishu , Chetelat, Gaël, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hansson, Oskar H., Huang, Q., Huang, Shu‐Hua , Ishii, Kenji, Jagust, William J., Kato, Takashi , Koeppe, R. A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J. , Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C. , Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis G., Rowe, C. C., Schott, Jonathan M, Schwartz, Daniel L. , Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz, Smith, Ruben, Sokołowski, Andrzej , Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, David E. , Flier, Wiesje M. van der, Vemuri, Prashanthi, Villain, Nicolas , Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Wang, Wei‐en , Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Casaletto, Kaitlin B. , Cash, David M. , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Brad C., Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kazunari , Jagust, William J. , Kramer, Joel H. , Landau, Susan, Landeau, Brigitte , Masters, Colin L. , Mézenge, Florence, Nakamura, Akinori , O’Bryant, Sid E. , Peretti, Débora Elisa , Quenon, Lisa , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Sokolowski, Andrzej, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110011 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen’s kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure‐1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure‐1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure‐2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure‐2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Multi‐omics studies reveal convergent and divergent pathways in Alzheimer's and related disorders
Allen, Mariet , Oatman, Stephanie R., Wang, Xue, Reddy, Joseph S. , Nguyen, Thuy T. , Ertekin‐Taner, Nilüfer, Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_096030 Get It

Abstract Background Alzheimer's disease (AD) is pathologically characterized by the presence of extracellular amyloid beta plaques and intracellular tau tangles. Related disorders share aspects of AD pathology including progressive supranuclear palsy (PSP), a tauopathy, and pathologic aging (PA) defined by presence of amyloid but not tau. We hypothesize that there are shared, and distinct, brain molecular changes associated with amyloid and tau protein levels in AD and related disorders and that identifying these will provide novel insights into disease pathogenesis. Methods We collected brain multiomics measures (genetic, transcriptomic, epigenomic, proteomic and metabolomic) from donors diagnosed with AD, PSP, PA and controls. Following quality control and normalization, omics measures were tested for association with disease diagnosis and amyloid and tau neuropathology using regression models adjusting for relevant covariates. Association with biochemical measures of core AD proteins were also assessed in a subset of AD cases. Gene sets were evaluated for enrichment of cellular pathways and cell type signatures. Results We found remarkably conserved transcriptomic changes associated with AD and PSP, and downregulation of myelination pathway genes in both diseases. Among PSP cases, we found divergent patterns of transcriptional associations with distinct tau lesions. In a cohort of AD cases, we found broad transcriptional and epigenetic dysregulation associated with levels of tau protein, but not amyloid beta. Conversely a genetic analysis implicated more variants associated with amyloid levels than tau. Conclusion Multi‐omics studies across various proteinopathies can identify convergent and divergent molecular signatures that are candidates for shared therapeutic targets and disease differentiating biomarkers.